1. Home
  2. STGW vs PCRX Comparison

STGW vs PCRX Comparison

Compare STGW & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STGW
  • PCRX
  • Stock Information
  • Founded
  • STGW 1980
  • PCRX 2006
  • Country
  • STGW United States
  • PCRX United States
  • Employees
  • STGW N/A
  • PCRX N/A
  • Industry
  • STGW
  • PCRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • STGW
  • PCRX Health Care
  • Exchange
  • STGW Nasdaq
  • PCRX Nasdaq
  • Market Cap
  • STGW 1.4B
  • PCRX 1.2B
  • IPO Year
  • STGW N/A
  • PCRX 2011
  • Fundamental
  • Price
  • STGW $5.00
  • PCRX $23.93
  • Analyst Decision
  • STGW Buy
  • PCRX Strong Buy
  • Analyst Count
  • STGW 6
  • PCRX 6
  • Target Price
  • STGW $8.46
  • PCRX $33.83
  • AVG Volume (30 Days)
  • STGW 5.1M
  • PCRX 785.4K
  • Earning Date
  • STGW 11-06-2025
  • PCRX 11-06-2025
  • Dividend Yield
  • STGW N/A
  • PCRX N/A
  • EPS Growth
  • STGW 1954.71
  • PCRX N/A
  • EPS
  • STGW 0.06
  • PCRX 0.47
  • Revenue
  • STGW $2,890,264,000.00
  • PCRX $716,791,000.00
  • Revenue This Year
  • STGW $4.18
  • PCRX $7.27
  • Revenue Next Year
  • STGW $9.16
  • PCRX $10.18
  • P/E Ratio
  • STGW $87.40
  • PCRX $50.46
  • Revenue Growth
  • STGW 6.75
  • PCRX 3.14
  • 52 Week Low
  • STGW $4.03
  • PCRX $16.00
  • 52 Week High
  • STGW $8.18
  • PCRX $27.64
  • Technical
  • Relative Strength Index (RSI)
  • STGW 49.83
  • PCRX 58.17
  • Support Level
  • STGW $4.70
  • PCRX $23.25
  • Resistance Level
  • STGW $6.88
  • PCRX $24.30
  • Average True Range (ATR)
  • STGW 0.33
  • PCRX 1.18
  • MACD
  • STGW 0.02
  • PCRX 0.37
  • Stochastic Oscillator
  • STGW 17.33
  • PCRX 78.91

About STGW Stagwell Inc.

Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: